{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:37:10Z","timestamp":1789472230235,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective study of patients with DT registered between 1995 and 2020 at All India Institute of Medical Sciences, New Delhi and Tata Medical Center, Kolkata. Baseline characteristics were analyzed in form of median values and interquartile range. Categorical and continuous variables were compared by chi square and independent samples T- tests respectively. Anxiety, depression and QoL were prospectively measured among 30 patients using Hospital Anxiety and Depression (HADS) and Functional Assessment of Cancer Therapy-General (FACT-G) scales respectively between 2022 to 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>200 patients were included with a male-predominant (n=111, 55.5%) population and median age 26.5 (2.5-75) years. Extremity (n=100, 50%) and abdomen (n=65, 32.5%) were commonest primary sites and median of 2 (1\u20134) lines of treatment were received. First-line included surgery (n=116, 58%), systemic therapy (n=67, 33.5%), radiotherapy (10, n=5%) and active surveillance (n=7, 3.5%). First-line systemic agents included tamoxifen (n=55, 27.5%), imatinib (n=7, 3.5%), sorafenib (n=1, 0.5%) and chemotherapy (n=4, 2%). 2019 onward, 3% and 63% underwent active surveillance and surgery respectively. Best radiological response obtained with tamoxifen was stable disease (SD) (n=76, 59%) and partial response (PR) (n=31, 24.2%). Best radiological response obtained with sorafenib was PR (n=17, 60.7%) and SD (n=9, 32.1%). Thirty patients underwent HADS and FACT-G scale assessment. Mean HADS-Anxiety subscale score was 3.6 (+\/-3.9 SD) and HADS-Depression sub-scale score was 2.6 (+\/-3.5 SD) with clinically significant anxiety and depression in 2 (6.7%) patients each. The overall mean FACT-G score was 87.5 (+\/-12.6 SD) and lower mean physical well-being (p=0.006) and emotional well-being (0.017) scores were significantly associated with higher HADS-anxiety (&amp;gt;\/=8) scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Assessment of anxiety, depression and QoL are paramount to gauge the psychological impact of DT. This study gives an overview of clinical and management profile of patients with DT in India, with limitations of selection bias, heterogeneous population and small sample size for QoL assessment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1382856","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:10:18Z","timestamp":1729483818000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India"],"prefix":"10.3389","volume":"14","author":[{"given":"Ghazal","family":"Tansir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryadev Narayan","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V. S.","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Alam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0281","article-title":"Desmoid tumors: clinical features and treatment options for advanced disease","volume":"16","author":"Kasper","year":"2011","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/RCT.0000000000000790","article-title":"Current update on desmoid fibromatosis","volume":"43","author":"Moorthy","year":"2019","journal-title":"J Comput Assist Tomogr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v128.16","article-title":"Evolving strategies for management of desmoid tumor","volume":"128","author":"Riedel","year":"2022","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v126.24","article-title":"Desmoid tumors: To treat or not to treat, That is the question","volume":"126","author":"Kasper","year":"2020","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"New Engl J Med"},{"key":"B6","volume-title":"Research C for DE and FDA approves nirogacestat for desmoid tumors","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-012-0759-z","article-title":"Metronomic chemotherapy in progressive pediatric Malignancies: old drugs in new package","volume":"79","author":"Bahl","year":"2012","journal-title":"Indian J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0324","article-title":"Metronomic chemotherapy vs best supportive care in progressive pediatric solid Malignant tumors: A randomized clinical trial","volume":"3","author":"Pramanik","year":"2017","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27811","article-title":"Metronomic therapy in pediatric oncology: A snapshot","volume":"66","author":"Pramanik","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","author":"Alman","year":"2020","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2022.03.008","article-title":"Management of desmoid tumors","volume":"31","author":"Spolverato","year":"2022","journal-title":"Surg Oncol Clinics North America"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1805","article-title":"Current management of desmoid tumors: A review","volume":"10","author":"Kasper","year":"2024","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000374","article-title":"Adult desmoid tumors: biology, management and ongoing trials","volume":"29","author":"Penel","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-014-9760-1","article-title":"Desmoid tumour in familial adenomatous polyposis patients: responses to treatments","volume":"14","author":"Desurmont","year":"2015","journal-title":"Fam Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pon.v29.2","article-title":"High prevalence of persistent emotional distress in desmoid tumor","volume":"29","author":"Ingley","year":"2020","journal-title":"Psychooncology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07445-0","article-title":"Health-related quality of life (HRQoL), anxiety, and depression in patients with desmoid type fibromatosis","volume":"30","author":"Garg","year":"2022","journal-title":"Support Care Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211000113","article-title":"Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma","volume":"28","author":"Sharma","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B19","unstructured":"Interpretation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The hospital anxiety and depression scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1470-2045(22)00688-X","article-title":"Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis","volume":"24","author":"Bhatia","year":"","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4386-8","article-title":"Desmoid fibromatosis through the patients\u2019 eyes: time to change the focus and organisation of care","volume":"27","author":"Husson","year":"2019","journal-title":"Support Care Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.008","article-title":"Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France","volume":"58","author":"Penel","year":"2016","journal-title":"Eur J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2203915","article-title":"Disease and economic burden of surgery in desmoid tumors: a review","volume":"23","author":"Fernandez","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.gastha.2023.01.010","article-title":"A review of the clinical presentation, outcomes, and treatments of patients having desmoid tumors","volume":"2","author":"Figueredo","year":"2023","journal-title":"Gastro Hep Adv"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejca.2020.06.022","article-title":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","volume":"137","author":"Timbergen","year":"2020","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2966","article-title":"Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial","volume":"25","author":"Skapek","year":"2007","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24457","article-title":"Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children\u2019s Oncology Group (COG) phase II study","volume":"60","author":"Skapek","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1177","article-title":"Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial","volume":"16","author":"Chugh","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.11050","article-title":"Efficacy of oral vinorelbine in advanced\/progressive desmoid tumours: An updated retrospective study in 50 patients","volume":"34","author":"Mir","year":"2016","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.028","article-title":"Functional analysis of young patients with desmoid-type fibromatosis: Initial surveillance does not jeopardize long term quality of life","volume":"46","author":"Duhil de B\u00e9naz\u00e9","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pon.v31.3","article-title":"Health literacy in communication, decision-making and outcomes among cancer patients, their families and clinicians in India: A multicentre cross-sectional qualitative study","volume":"31","author":"Harding","year":"2022","journal-title":"Psychooncology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v126.3","article-title":"Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis","volume":"126","author":"Gounder","year":"2020","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1382856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:10:22Z","timestamp":1729483822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1382856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":34,"alternative-id":["10.3389\/fonc.2024.1382856"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1382856","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"article-number":"1382856"}}